Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Sadick Research Group

Neither a doctor nor a teaching hospital

Research payments

$851,569

100 payments

Through program year 2025, Sadick Research Group is reported as receiving $851,569 in research payments, across 100 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $199,332 29
2024 Research $570,476 62
2023 Research $72,502 7
2019 Research $9,258 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $362,715 28 payments
  2. Pfizer Inc. $140,184 31 payments
  3. Sanofi US Services Inc. $114,592 8 payments
  4. GlaxoSmithKline, LLC. $108,022 21 payments
  5. Amgen Inc. $60,501 7 payments
  6. E.R. Squibb & Sons, L.L.C. $56,366 4 payments
  7. Celgene Corporation $9,188 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period $264,432 20 payments
  2. A Phase 2 Randomized Doubleblind Placebocontrolled Study to Investigate the Efficacy and Safety of Pf07275315 and Pf07264660 in Adult Participants With Moderatesevere Atopic Dermatitis $140,114 30 payments
  3. Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD $90,691 5 payments
  4. A Phase 2B, Randomized, Double-Blind, Parallel Group, Placebo Controll $88,735 17 payments
  5. TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis $83,873 7 payments
  6. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting $53,466 3 payments
  7. ASCEND P3 AD Extension $27,624 2 payments
  8. A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis $23,901 3 payments
  9. Long-Term Extension Study (Atdvance) to Evaluate the Safety and Effica $19,287 4 payments
  10. IGNITE P3 AD Adult Monotherapy Study 1 $15,414 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record